智通财经APP获悉，晶泰控股-P(02228)再涨超6%，截至发稿，涨6.27%，报7.12港元，成交额2.69亿港元。
国投证券发布研报称，受加速药物研发的需求增加、AI应用领域的拓展、配套政策的支持等多因素驱动，近年AI制药领域持续蓬勃发展。根据ResearchAndMarkets的数据，全球AI制药市场规模从2021年的7.92亿美元提升至2024年的17.58亿美元。随着AI主导的药物研发项目的成功率提升、相关研发管线持续取得进展，AI制药技术的进一步商业化应用值得期待。
海通证券此前指出，从2007年的早期探索至今，AI制药技术经历了技术积累、验证和快速发展期，目前正处于一个技术创新活跃、政策扶持明显、市场前景广阔的阶段。 AI制药技术的应用有望缩短药物研发周期，降低成本，提高研发成功率。AI技术使得从药物设计到临床试验的全流程更加高效，为传统药物研发带来创新变革，并展现出在药物研发领域的广阔前景和巨大潜力。随着AI技术的不断进步和CRO公司专业能力的增强，预计未来药物研发领域将迎来更多创新突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.